Tolvaptan

Tolvaptan tablets are indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). Limitations of Use: Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with tolvaptan tablets.

12.1 Mechanism of Action Tolvaptan is a selective vasopressin V 2 -receptor antagonist with an affinity for the V 2 -receptor that is 1.8 times that of native arginine vasopressin (AVP). Tolvaptan affinity for the V 2 -receptor is 29 times greater than for the V 1a -receptor. When taken orally, 15 to 60 mg doses of tolvaptan antagonize the effect of vasopressin and cause an increase in urine water excretion that results in an increase in free water clearance (aquaresis), a decrease in urine osmolality, and a resulting increase in serum sodium concentrations.

Clinical clearance of Tolvaptan (Vasopressin V2 Receptor Antagonist) relies on systemic clearance of tolvaptan integrates hepatic phase ii conjugation with renal filtration with a Elimination kinetics span 11 to 24 hours per Tolvaptan clinical pharmacology half-life; patients absorbing at Consistent 51%–63% gastrointestinal absorption profile for Tolvaptan bioavailability typically observe target onset around cmax attained 2–3 hours post-administration of tolvaptan.

FDA clinical labeling for Tolvaptan restricts administration in tolvaptan tablets are contraindicated in the following conditions:; patients with autosomal dominant polycystic kidney disease (adpkd) outside of fda-approved rems; unable to sense or respond to thirst across Kit, 30 mg/1 Tablet, 60 mg/1 Tablet, 15 mg/1 Tablet, 45 mg/1 Tablet, with self-reported patient tracking dominated by nausea (8.4% of reports), headache (7% of reports), constipation (7% of reports).